Prediction of the responsiveness to treatment with erythropoiesis- stimulating factors: A prospective clinical study in patients with solid tumors

Oncologist

Volumn 12, Issue 6, 2007, Pages 748-755

  Steinmetz, H Tilman ^a,h   Hellmich, Martin ^f   Neise, Michael ^b   Aldaud, Ali ^c   Lerchenmüller, Christian ^d   Tsamaloukas, Antonis ^e   Fandel, Francoise ^a   Weiligmann, Christoph ^d   Totzke, Uwe ^g   Schmitz, Stephan ^a  

^a Oncological Outpatient Clinics   (Germany)

^b Oncologic Outpatient Clinics   (Germany)

^c Oncologic Outpatient Clinics   (Germany)

^d Oncologic Outpatient Clinics   (Germany)

^e Oncologic Outpatient Clinics   (Germany)

^f UNIVERSITY OF COLOGNE   (Germany)

^g Healthcare Project Management   (Switzerland)

^h NONE   (Germany)

Author keywords

Anemia; Corresponding receiver operating characteristic curve; Erythropoietic proteins; Predictive factors

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN RECEPTOR;

ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG WITHDRAWAL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE; SOLID TUMOR; TREATMENT OUTCOME;

AGED; ANEMIA; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; ROC CURVE; TREATMENT OUTCOME;

EID: 34447115636     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-6-748     Document Type: Article

References (32)

1. Khayat D. Is anemia a problem for European cancer patients and treating oncologists? Semin Oncol 2000;27(suppl 4):9-11; discussion 16-17.
2. Barrett-Lee PJ, Bailey NP, O'Brien ME et al. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 2000;82:93-97.
3. Ashbury FD, Findlay H, Reynolds B et al. A Canadian survey of cancer patients' experiences: Are their needs being met? J Pain Symptom Manage 1998;16:298-306.
4. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACTAn) Scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34(suppl 2):13-19.
5. Fein DA, Lee WR, Hanlon AL et al. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 1995;13:2077-2083.
6. Dubray B, Mosseri V, Brunin F et al. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: A prospective study. Radiology 1996;201:553-558.
7. Waters JS, O'Brien ME, Ashley S. Management of anemia in patients receiving chemotherapy. J Clin Oncol 2002;20:601-603.
8. Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
9. Glaser CM, Millesi W, Kornek GV et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001;50:705-715.
10. Heiss MM, Mempel W, Delanoff C et al. Blood transfusion-modulated tumor recurrence: First results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol 1994;12:1859-1867.
11. Jensen LS, Kissmeyer-Nielsen P, Wolff B et al. Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet 1996;348:841-845.
12. Malik IA, Khan ZK, Hakimali A et al. The effect of subcutaneous recombinant human erythropoietin (r-HuEPO) on anemia in cancer patients receiving platinum-based chemotherapy. J Pak Med Assoc 1998;48:127-131.
13. Goram AL. Factors and predictors of response with epoetin alfa for chemotherapy-related anemia. J Pharm Technol 2000;16:227-235.
14. Cazzola M, Ponchio L, Pedrotti C et al. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica 1996;81:434-441.
15. Littlewood TJ, Zagari M, Pallister P. Pretreatment erythropoietin levels cannot be used to predict individual response to epoetin alfa in anaemic cancer patients. Curr Med Res Opin 2005;21(suppl 2):S19-S21.
16. Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40:2201-2216.
17. Kolesar JM, Duren BA, Baranski BG. Retrospective evaluation of response to epoetin alfa in patients with hematologic disorders. J Oncol Pharm Pract 2004;10:1-6.
18. Littlewood TJ, Zagari M, Pallister C et al. Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients. The Oncologist 2003;8:99-107.
19. Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258-270.
20. Katodritou E, Speletas M, Kapetanos D et al. Evaluation of traditional and novel predictive markers of anemia response to recombinant human erythropoietin (rh-EPO) in patients with multiple myeloma and lymphoma: Emerging role of functional iron deficiency. Blood 2004;104:8B.
21. Katodritou E, Speletas M, ZervasKet al. Evaluation of hypochromic erythrocytes in combination with sTfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma. Lab Hematol 2006;12:47-54.
22. Gonzalez-Baron M, Ordonez A, Franquesa R et al. Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy. Cancer 2002;95:2408-2413.
23. Trelle S, Piper M, Bohlius J et al. Predictive factors of response to recombinant human erythropoietin: Quality and results of studies identified by a systematic review. Onkologie 2006;29(suppl 3):66.
24. Canon JL, Vansteenkiste J, Bodoky G et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006;98:273-284.
25. Vansteenkiste J, Pirker R, Massuti B et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-1220.
26. Hedenus M, Adriansson M, San Miguel J et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies:A randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403.
27. Glaspy J, Henry D, Patel R et al. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa:Arandomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer 2005;41:1140-1149.
28. Beguin Y, Yerna M, LooMet al. Erythropoiesis in multiple myeloma: Defective red cell production due to inappropriate erythropoietin production. Br J Haematol 1992;82:648-653.
29. Harrell F Jr. Regression Modeling Strategies. New York: Springer, 2001:1-568.
30. Cheer SM, Wagstaff AJ. Epoetin beta: A review of its clinical use in the treatment of anaemia in patients with cancer. Drugs 2004;64:323-346.
31. Cazzola M, Beguin Y, Kloczko J et al. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003;122:386-393.
32. Lastiri JM, Specterman SR, Rendo P et al. [Predictive response variables to recombinant human erythropoietin treatment in patients with anemia and cancer.] Medicina (B Aires) 2002;62:41-47.